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Primary ciliary dyskinesia (PCD) is a rare, autosomal recessive
disorder of motile cilia that leads to oto-sino-pulmonary
disease.1 PCD was first described by Kartagener et al in
1936 as a syndrome based on the triad of chronic sinusitis,
bronchiectasis, and situs inversus. Forty years later, Afzelius
expanded on this by observing that these patients had
“immotile” cilia and defective ciliary ultrastructure, specifi-
cally noting a deficiency of dynein arms, decreased mucocili-
ary clearance, and a lack of ciliary motion.2,3 Later on, the
syndrome was renamed “primary ciliary dyskinesia”when it
was observed that functional ciliary impairment without
ultrastructural deformities, as well as motile cilia with obvi-
ous abnormal movement patterns, could result in clinical
disease.4–6 The prevalence of PCD is difficult to determine due
to (hitherto) inadequate diagnostic methods and often an
under-recognition of the syndrome; it is estimated to be
approximately 1 in 15,000 to 20,000 individuals.7 Focused
clinical and research efforts in recent years have led to an
increased understanding of the phenotype, as well as the
discovery of PCD-causing genetic mutations. Indeed, the use
of genetic testing has greatly aided the diagnosis of PCD and
further helped the understanding of PCD. Nonetheless, even
with improvements in diagnostic and screening tests at
specialized centers, up to 30% of patients may be missed.
Secondary ciliary dyskinesia may be seen in diseases associ-
ated with acute and chronic airway inflammation and
infection.
This review focuses primarily on PCD, the genetically
transmitted form of the disease, with a brief review of the
structure and function of normal and dysfunctional cilia, the
clinical manifestations of PCD, including diagnosis, genetic
mutations, therapies, and a glimpse into future.
Normal Cilia Structure and Function
Respiratory cilia are an important part of airway host defense,
protecting the airways from inhaled pathogens, allergens,
and other inhaled noxious particles via the mucociliary
escalator. In the airways, they are surrounded by a thin,
watery, periciliary fluid layer overlaid by a more viscous
mucus layer. The efficiency of the mucociliary escalator in











Abstract Primary ciliary dyskinesia (PCD) is an autosomal recessive disorder of cilia structure,
function, and biogenesis leading to chronic infections of the respiratory tract, fertility
problems, and disorders of organ laterality. The diagnosis can be challenging, using
traditional tools such as characteristic clinical features, ciliary function, and ultrastruc-
tural defects and newer screening tools such as nasal nitric oxide levels and genetic
testing add to the diagnostic algorithm. There are 32 known PCD-causing genes, and in
the future, comprehensive genetic testing may screen young infants before developing
symptoms, thus improving survival. Therapies include surveillance of pulmonary
function andmicrobiology, in addition to airway clearance, antibiotics, and early referral
to bronchiectasis centers. As with cystic fibrosis (CF), standardized care at specialized
centers using a multidisciplinary approach likely improves outcomes. In conjunction
with the CF foundation, the PCD foundation, with experienced investigators and
clinicians, is developing a network of PCD clinical centers to coordinate the effort in
North America and Europe. As the network grows, clinical care and knowledge will
improve.
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composition of the periciliary fluid and mucus layer, the
integrity of the airway epithelium, and the synchrony and
beat frequency of the cilia. The density of cilia decreases from
the upper to the lower respiratory tract with an absence of
cilia in the alveoli and air sacs.8 Cilia are hair-like attachments
found on the epithelial cell surfaces (200 per cell) of various
organs. The cilia basal body attaches to the apical cytoplasm
on the cell surface and extends into the extracellular space.
They are composed of α- and β-tubulin monomers organized
into longitudinal microtubules. The axonemal structure con-
sists of a circular arrangement of nine microtubule doublets
surrounding a central pair of microtubules (9 þ 2) or with an
arrangement where the central pair is absent (9 þ 0).9 Cilia
are categorized into 9 þ 2 motile cilia with dynein arms,
9 þ 0 motile cilia (nodal cilia) with dynein arms, and 9 þ 0
nonmotile cilia lacking dynein arms.10
“9 þ 2” motile cilia are found on the apical surfaces of the
upper and lower respiratory tract, on the ependymal cells
lining the ventricles of the central nervous system, in the
oviducts, and in the flagellum of sperm.10 Outer dynein arms
(ODAs) and inner dynein arms (IDAs) traverse along the
length of the peripheral microtubules forming a doublet
(►Fig. 1) and are organized into nine microtubule pair
doublets, surrounding a central pair. This organizational
structure creates this distinctive 9 þ 2 arrangement. The
central pair is linked to the surrounding pair doublet through
radial spoke proteins, and the surrounding pair doublets are
linked to one another via nexin-linked proteins (►Fig. 1). The
microtubules slide by one another to produce ciliary motion
via an ATP-containing dynein arm on the peripheral micro-
tubule. The protein links between the microtubules limit the
degree of sliding, causing them to bend. Through coordinated
and synchronized bending, wave-like movements occur at
approximately 6 to 12 Hz, which function to propel mucus
and adherent particles/bacteria on the surface of the airway—
hence the term “mucociliary escalator.” The ability of numer-
ous adjacent cilia on airway epithelial cells to beat at such a
high frequency in part reflects the very low friction among
the cilia, which results from negatively charged glycoproteins
that coat the ciliary shaft. Thus, given such an efficient, if
complex, system of defense, it can readily be visualized that
clinical disease may result from disruptions in the various
components of the system. For example, cystic fibrosis (CF)
results from abnormalities in the CF transmembrane conduc-
tance regulator, a critical airway surface epithelial protein.
Similarly, mutations in genes encoding for axonemal struc-
tures of the functional components of motile cilia, or proteins
involved in the biogenesis of cilia, including cytoplasmic
proteins, can result in clinical disease (PCD).11–14
Although dysfunctional motile cilia lead to the main clini-
cal manifestations of PCD, abnormal nodal motile cilia can
also lead to interesting phenotypic features. Nodal cilia occur
during embryonic development and have a 9 þ 0 configura-
tion rather than the classic 9 þ 2 configuration and are found
on the epithelial cell surface of the kidneys, the bile ducts, and
the endocrine pancreas and on nonepithelial cells such as
chondrocytes, fibroblasts, smooth muscle cells, and neurons.
In contrast to the waveform sliding motion of 9 þ 2 cilia,
nodalmotile 9 þ 0 cilia beat with a vertical/rotationalmotion
resulting in a leftward flow of extracellular fluid which is
important for cell signaling during the development of nor-
mal human left–right asymmetry.Mutations in the genes that
encode the outer doublets result in laterality defects (e.g.,
situs inversus), while mutations in the genes that encode the
nondirectional central apparatus (central complex, radial
spoke) do not.15 This represents a predictable genotype–
phenotype relationship (see section “Genetic Testing”).
Phenotypic Features
Overview
Cells lining the nasopharynx, middle ear, paranasal sinuses,
the lower respiratory tract, and the reproductive tract contain
cilia; these cilia are abnormal in structure and function in
PCD, leading to clinical expression of disease. The clinical
manifestations of PCD are thus predictable, with an age-
dependent and organ system spectrum of presentation
(►Table 1). Symptoms of PCD can occur at birth, or within
the first several months of life. Normal ciliary function is
critical in the clearance of amniotic fluid from the fetal lung;
more than 80% of full-term neonates with PCD have a
syndrome of respiratory distress. Unexplained respiratory
distress, radiographic abnormalities, atelectasis in particular,
and hypoxia in a full-term infant should raise the suspicion
for PCD.16,17 Almost all children with PCD have a daily
productive cough, a logical symptom, as cough can partially
compensate for the dysfunctional mucociliary clearance.
However, recurrent bacterial infections of the lower airways
ultimately lead to bronchiectasis, which is seen in virtually all
older adults with PCD.16–18 Despite aggressive medical care,
PCD is generally a progressive disease and some patients
develop severe disease, respiratory failure, and/or require
lung transplant (►Fig. 2).1
Airway Microbiology
Regular surveillance of the respiratory flora is important, as
a variety of organisms may colonize or infect the lung,
which may require targeted therapy because of resistance,
or lead to specific infectious problems (e.g., nontuberculous





Outer dynein arm (ODA)
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Fig. 1 Diagrammatic representation of a normal ciliary cross section
illustrating major ultrastructural components.
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CF and PCD patients vary, but most centers obtain airway
cultures every 3 to 6 months. The respiratory microbiology
in PCD generally mirrors that of CF; however, in PCD
colonization with Pseudomonas aeruginosa, it generally
occurs later, and the incidence of Streptococcus pneumoniae
is much higher.1 Children with PCD have airway coloniza-
tion with Haemophilus influenza, Staphylococcus aureus,
and S. pneumoniae and recently, there has been an upsurge
of P. aeruginosa in infants/preschoolers. P. aeruginosa
(smooth and mucoid varieties) normally occurs in teen-
agers and young adults and is often the dominant organism
in adults with PCD. NTM are seen in approximately 15% of
adults with PCD.1
Lung Function
Patients with PCD, as with other patients with non-CF bron-
chiectasis, usually develop progressive airway obstruction as
the disease advances. The disease progression is usually slower
than that seen in CF; however, it is just as important to follow
lung function serially to establish a baseline, to help guide
therapy, and to determine prognosis.18–20
Radiology
High-resolution chest computed tomography scan (HRCT scan)
is the most sensitive imaging modality to diagnosis bronchiec-
tasis. While HRCT cannot confidently distinguish between the
different etiologies for bronchiectasis (PCD vs. idiopathic vs.
postinfectious disease), there are disease distributions that
may support specific diseases. For example, PCD may be associ-
atedwith more bronchiectasis in the middle and lower lobes, as
compared with CF which usually shows more disease in upper
lobes.21 Subtle lung disease may start early in life, as HRCTscans
of infants and childrenwith PCD show subsegmental atelectasis,
peribronchial thickening, mucus plugging, evidence of air trap-
ping, and groundglass opacities. HRCTmay show bronchiectasis
even in infancy, and its frequency increases with age. The
absence of bronchiectasis on a HRCT scan of an adult virtually
excludes PCD from the differential.21,22
Nonpulmonary Manifestations
Situs abnormalities result in early diagnosis; thus, it is found in
approximately 60% of newly diagnosed pediatric patients and
approximately 50% of newly diagnosed adults. The defect is in
the 9 þ 0 nodal motile cilium during embryogenesis whose
unidirectional rotational beat determines normal thoracoabdo-
minal orientation. Without this, thoracoabdominal orientation
develops at random, resulting in a 50% incidence in adults.15
Recently, this phenotypic expression of situs abnormalities has
expanded to include other clinicalmanifestations, including that
of cardiac abnormalities; approximately 6% of patients with PCD
have congenital heart disease.23 Spermatozoa dependon cilia for
motility; thus, infertility is seen in almost all males with PCD.
However, a small number of men with PCD have appeared to
conceive naturally. Females have abnormal cilia in their fallopian
tubes with longer ovum transit time, and there appears to be an
increased incidence of infertility and ectopic pregnancies.24 Less
clear phenotypic associations include pectus excavatum (10%),
scoliosis (5–10%), retinitis pigmentosa, and hydrocephalus.25
Diagnostic Approaches
A precise diagnosis of PCD may be difficult, especially in
nonclassic clinical situations (e.g., without situs abnormali-
ties). Often, only specialized centers have the resources to
make a definitive diagnosis (see later). Obviously, the presence
Table 1 Clinical signs and symptoms of primary ciliary dyskinesia
By system affected By age of presentation
Middle ear
• Chronic otitis media with tube placement
• Conductive hearing loss











• Male/female fertility problem or history of in vitro
fertilization
Laterality defects
• Situs inversus totalis







• Communities or ethnicities with consanguinity
• Close (usually first degree) relatives with clinical
symptoms
Antenatal
• Heterotaxy on prenatal ultrasound
Newborn period
• Continuous rhinorrhea
• Respiratory distress or neonatal pneumonia
Childhood
• Chronic productive cough
• Atypical asthma unresponsive to therapy
• Idiopathic bronchiectasis
• Chronic rhinosinusitis
• Recurrent otitis media with effusion
Adolescence and adult life
• Same as for childhood
• Subfertility and ectopic pregnancies in females
• Infertility in males with immotile sperm
• Sputum colonization with nontuberculosis mycobacte-
rium or smooth/mucoid pseudomonas
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of any laterality abnormalities, or congenital heart disease, in
the presence of chronic respiratory disease should prompt the
notion of PCD as a potential unifying cause. A history of
unexplained neonatal respiratory distress, early onset and
persistent nasal-pulmonary symptoms, unexplained bronchi-
ectasis, a family history of PCD, and immotile sperm/infertility
should trigger an evaluation. There is overlap with other
chronic respiratory diseases, particularly CF, although immu-
nologic deficiencies, allergic bronchopulmonary aspergillosis
(ABPA), and recurrent aspirationmayalso be in the differential.
Early referral to a specialized center is recommended for both
diagnosis and management, given the complex nature of the
disease, and the rapid nature with which new information is
emerging in relation to diagnosis and management.
Indirect Assessment of Ciliary Function
Saccharin test—The saccharin test was a traditional, simple,
indirect way to test ciliary function, and was used as a
screening tool for PCD at many centers. A 1- to 2-mm particle
of saccharin is placed on the inferior nasal turbinate and
the time it takes the patient to taste the saccharin is a
rough estimate of nasal mucociliary clearance. However, at
best it is crude, limited by technical errors (inadequate
placement of saccharin), patient compliance (unable to sit
still for test, especially children), and false positives
(poor sense of taste, rhinosinusitis). Thus, it is rarely used
currently, and has been superseded by the more accurate
tests below.
Nasal nitric oxide (NO) levels—The fortuitous observation
several years ago that levels of NO produced in the upper
airway are reduced in PCD led to the concept that nasal NO
levels could be used as screening test in PCD.26NO is produced
by the paranasal sinus epithelium via NO–synthase and low
levels are seen in PCD, CF, acute/chronic sinusitis, and nasal
polyposis. In patients with PCD, however, levels of exhaled NO
are extremely low (10% of normal value) when compared
with other diseases. Interestingly, carriers of PCD have been
shown to have intermediate levels of exhaledNO.1,27,28Using a
Clinical suspicion of PCD 
CT chest with bronchiectasis 
No 
PCD unlikely* 
Other etiologies of bronchiectasis 
excluded 
Yes • Exclude cystic fibrosis with a sweat chloride test 
and/or CFTR gene mutation analysis
• Exclude primary immunodeficiency with 
immunoglobulin levels; IgG, IgA and IgM, serum 
electrophoresis, response to vaccines 
• Exclude connective tissue disorders with appropriate 
serologic tests 
• Consider ABPA, asthma, allergic rhinitis, reflux, 
and α1-antitrypsins deficiency
No
Nasal NO level reduced 





via nasal biopsy 
Ciliary beat frequency and pattern PCD not excluded***
Nml 
Abnml 
Electron microscopy with 
ultrastructural defect in cilia Normal beat frequency, pattern and 
ultrastructure makes PCD unlikely 
PCD likely 
Yes
Consider genetic testing  
Yes 
Nml
Fig. 2 Diagnostic algorithm for PCD. If clinical suspicion is still high for PCD, may go to other, more specific tests. A nasal NO level less than 77
nL/min has a sensitivity and specificity of 0.98 and>0.99, respectively. Normal ciliary beat frequency and pattern does not exclude PCD. Abnml,
abnormal; Nml, normal; NO, nitric oxide; PCD, primary ciliary dyskinesia.
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standardized protocol, nasal NOmeasurements can accurately
identify patients with PCD 98.6% of the time.29
Direct Assessment of Ciliary Function
Microscopic analysis—Function can be classed as qualitatively
normal, dyskinetic, or immotile with direct visualization of
ciliary beat pattern and frequency with microscopic analysis
of transnasal brushings or nasal scrapes of the inferior turbi-
nate. However, this test is technically difficult outside of
research centers, and is neither sensitive nor specific.30
High-speed digital video imaging—Transnasal brushing or
nasal scrape ciliated epithelial samples can be analyzed
with high-speed digital video imaging to get quantitative
measurements of the ciliary beat frequency (CBF) to help
differentiate between abnormally beating cilia and normal
beat patterns.9,31 The cilium can be viewed in slow motion,
with 40 to 50 frames per ciliary beat cycle. Normal cilia beat
back and forth within the same frame with no sideways
recovery sweep. CBF and beat pattern abnormalities are
associated with specific ultrastructural defects including
transposition and defects in isolated outer arms, isolated
inner arms, and radial arms.32 Active sinusitis can cause
secondary ciliary dysfunction resulting in false positives,
and thus samples should be obtained when the patient is
relatively stable clinically. A normal CBF and beat pattern is
sensitive enough to exclude classic PCD, but any abnormal-
ity should provoke further testing.27 Thus, this test (like
other studies of cilia, often available at only research
centers) should be used along with structural and genetic
analysis to confirm the diagnosis.
Assessment of Ciliary Ultrastructure
Transmission electron microscopy 33—Once the suspicion for
PCD is high, the axonemal structure of the respiratory cilia
may be studied using transmission electron microscopy, the
traditional way of diagnosing PCD since Afzelius’ first report
in themid-1970s.2Various ciliary ultrastructural defects have
been described, including the absence of, or alteration in, IDAs
or ODAs, absence of the central pair, or defect of radial
spokes.34 The most common ultrastructural defect in PCD is
either the absence or shortening of an ODA (55% prevalence)
or a combined of absence/shortening of both the IDA and the
ODA (15% prevalence). Other abnormalities include defects in
the IDA alone or in combinationwith defects in radial spokes,
central microtubule pairs (transposition), or central microtu-
bular agenesis. Thus, until recently, the identification of
ultrastructural defects on TEM was the “gold standard” for
the diagnosis; however, with advances in our molecular
understanding in PCD, it is known that approximately 30%
of patients with genetically proven PCD have normal ciliary
ultrastructure and in some cases, a ciliary or oligoplasia,
hence inadequate for the TEM analysis. In addition, the
technique is limited by false-positive conditions (those asso-
ciated with active mucosal epithelium inflammation, viral or
bacterial), inadequate samples, poorly processed samples,
and reader error.35–38 Studies have shown a 3 to 10% preva-
lence of defective cilia in the airways of healthy individuals,
and normal ultrastructure in up to 15% of PCD patients.39
Dependence on TEM alone therefore is an unreliable way of
solely diagnosing PCD.
Fluorescence-labeled antibodies—Immunofluorescent anal-
ysis using antibodies directed against the main axonemal
components has been used to identify structural abnormalities
of cilia. For example, PCD patients with ODA defects have
absence of DNAH5 staining from the entire axoneme and
accumulation of DNAH5 at the microtubule organizing center.
Antibody-based techniques can diagnose defects in both the
ODAs and the IDAs caused by the KTU mutation in PCD.
Currently, a panel of antibodies directed toward multiple
ciliary proteins is being developed that may add to the
diagnostic armamentarium in screening for PCD; however,
like many sophisticated techniques, it is restricted to a few
centers that have this technology.40
Genetic Testing
PCD is a recessive disorder, and exhibits locus and allelic
heterogeneity. That is,multiple genes are involved in thedisease,
and different mutations in the same gene may also cause PCD.
Mutations in 11 different PCD-causing genes have been
described between 1999 and 2010 with linkage mapping and/
or candidate gene testing. An additional 23 genes have been
discovered since 2011 owing to the availability of whole-exome
sequencing (►Table 2). Some of these genes (e.g., DNAH8 and
NME8) have only been seen in few patients; thus, replication
studies are necessary. About 80% of the mutations are loss-of-
function variants (nonsense, frame shift, or defective splice
mutations), while the others are conservative missense muta-
tions or in-frame deletions. Most mutations occur in only one
patient/family (“private” mutations); a few of the mutations
have been seen to recur in two or more unrelated patients.
Collaborative efforts in recent years have allowed the collection
of large amounts ofdata frommanyclinical centers in theUnited
States andCanada and thus facilitated large-scale genetic studies
and identification ofmany causative genes, which had previous-
ly been very difficult to do in this rare disease.41 Approximately
65% of the 200 PCD patients in the rare disease consortium
(Genetic Disorders of Mucociliary Clearance [GDMCC]) have
biallelic mutations (mutations in both copies of the same
gene). At this point, with the use of next generation sequencing,
approximately 66% of patients with PCD can be identified, thus
facilitating early diagnosis and treatment.40,42–45 This is espe-
cially helpful in the caseswhere ciliary ultrastructural analysis is
equivocal or inadequate.
As the basic structure of the cilia is highly conserved across
species, nonhuman models have helped in the discovery of PCD
genes and the effects of the mutations on the cilia. Multiple
publications have documented the effects of specific mutations
on the cilia structure and function. Some of the genes code for
proteins in the ODA, IDA, or radial spoke causing specific
dysfunction or dysmotility, while others are expressed by
proteins in the cytoplasm used for the preassembly of the cilia
causing loss of both the ODA and the IDA leading to cilia
immotility.43,46–48 Recently, two proteins (CCNO and MCIDAS)
havebeen shown to affect cilia biogenesis.49,50 Specific classes of
mutations are associatedwith specific phenotypes.Mutations in
genes that lead to loss of function of the cilia also lead to low
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Axonemal component Ultrastructure defect aPhenotype,
gene OMIM no.
PCD locus
DNAH5 5p15.2 ODA dynein HC ODA defect 608644, 603335 CILD3
DNAI1 9p21-p13 ODA dynein IC ODA defect 244400, 604366 CILD1
DNAI2 17q25 ODA dynein IC ODA defect 612444, 605483 CILD9
DNAL1 14q24.3 ODA dynein LC ODA defect 610062, 614017 CILD16
TXNDC3
(NME8)
7p14-p13 ODA dynein IC/LC Partial ODA defect (66%
cilia defective)
610852, 607421 CILD6
CCDC114 19q13.32 ODA DC ODA defect 615067, 615038 CILD20





ODA defect 615451, 615408 CILD23
DNAAF1
(LRRC50)
16q24.1 Cytoplasmic DA preas-
sembly factor
ODA þ IDA defect 613193, 613190 CILD13
DNAAF2
(KTU)
14q21.3 Cytoplasmic DA preas-
sembly factor
ODA þ IDA defect 612518, 612517 CILD10
DNAAF3
(C19ORF51)
19q13.42 Cytoplasmic DA preas-
sembly factor
ODA þ IDA defect 606763, 614566 CILD2
CCDC103 17q21.31 Cytoplasmic DA attach-
ment factor
ODA þ IDA defect 614679, 614677 CILD17
C21orf59 21q22.1 Cytoplasmic DA assembly
or adaptor for transport
ODA þ IDA defect 615500, 615494 CILD26
DYX1C1 15q21.3 Cytoplasmic DA preas-
sembly factor
ODA þ IDA defect 615482, 608706, CILD25
LRRC6 8q24 Cytoplasmic DA preas-
sembly and/or transport
ODA þ IDA defect 614935, 614930 CILD19
HEATR2 7p22.3 Cytoplasmic DA preas-
sembly or transport
ODA þ IDA defect 614874, 614864 CILD18
SPAG1 8q22 Cytoplasmic DA preas-
sembly or transport
ODA þ IDA defect 615505, 603395 CILD28
ZMYND10 3p21.31 Cytoplasmic DA assembly ODA þ IDA defect 615444, 607070 CILD22
CCDC39 3q26.33 N-DRC IDA defect þ microtubu-
lar disorganization
613807, 613798 CILD14





12q13.12 N-DRC Mostly normal, CA defects




2p23.3 N-DRC Nexin (N-DRC) link miss-
ing; axonemal disorgani-
zation in small proportion
of cilia
615294, 615288 CILD21
RSPH1 21q22.3 RS component Mostly normal, CA defects
in small proportion of cilia
615481, 609314 CILD24
RSPH4A 6q22.1 RS component Mostly normal, CA defects
in small proportion of cilia
612647, 612649 CILD11
RSPH9 6p21.1 RS component Mostly normal, CA defects
in small proportion of cilia
612650, 612648 CILD12
HYDIN 16q22.2 CA component Normal, very occasionally
CA defects
608647, 610812 CILD5
DNAH11 7p21 ODA dynein HC Normal 611884, 603339 CILD7
CCNO 5q11.2 Required for cilia
biogenesis
Ciliary a/oligoplasia 615872, 607752 CILD29
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nasal NO levels (<77 nL/min). Mutations that affect the dynein
arm’s ultrastructure lead to situs abnormalities, whilemutations
that affect the central apparatus do not. Mutations in patients
with normal TEM can have cilia with normal beat frequencies
and waveforms.
Overall, the more that is learnt about themolecular basis of
PCD, the more is learnt about the spectrum of phenotypes,
ranging from “classic” to mild, that is associated with late
presentation or normal cilia structure, analogous to the expe-
rience with CF—classic, early presentation disease versus non-
classic disease often presenting later in life, or even well into
adulthood.
Therapies
As there are currently no therapies available that can reverse
the underlying ciliary abnormalities, the goals of therapy are
to prevent exacerbations and slow down the progression of
the disease. As with other forms of CF and non-CF bronchiec-
tasis, patient education is a critical part of the care plan,
including imparting an understanding of the underlying
cause of the disease, its prognosis, and the various therapies
available to try to control the symptoms, especially airway
clearance. Currently, there are no data from randomized
clinical trials to support any particular forms of therapy;
thus, most management strategies (including those discussed
later) are extrapolated from CF and non-CF bronchiectasis. As
with any chronic disease, usual good health practices such as
refraining from smoking and administration of recom-
mended immunizations including influenza and pneumococ-
cal vaccines are recommended.
Surveillance
To guide the management plan, regular (twice yearly to
quarterly) lung function testing, together with microbiologic
assessments of airway flora (using either expectorated sputum
or induced samples using 3–7% hypertonic saline), is recom-
mended to establish clinical trends and detect exacerbations,
thus allowing targeted antimicrobial therapy. A baseline CT
scan is useful to assess the nature and extent of disease (as
noted earlier, bronchiectasis may be evident even in young
patients), followed by periodic chest imaging to track disease
progress or to assess the significance of new pathogens such as
multidrug-resistant gram-negative organisms or NTM.
Airway Clearance
Physiotherapy—There are no data to support any particular
form of airway clearance in PCD, but clinical experience
supports its use in a form acceptable to the patient. Daily
airway clearance with cardiovascular exercise, use of per-
cussion vests, manual chest physical therapy, and valve/
positive pressure expiratory devices help mobilize and aid
expectoration of bronchopulmonary secretions, improve
efficiency of ventilation, maintain/improve exercise toler-
ance, and reduce breathlessness.
Osmotic agents—“Hydration” therapy of the airway is an
attractive concept to augment clearance of secretions in a
disease such as PCD, in this case “cough clearance” given the
dysfunctional cilia.51 Nebulized hypertonic saline (3–7% hy-
pertonic saline) modulates the liquid content of the pericili-
ary fluid layer via increased hydration, thinning thick
secretions and triggering cough in the CF population. It has
been shown to improve lung function, quality of life, and
reduce antibiotic needs in the non-CF bronchiectasis popula-
tion.51,52 Recently, another agent which works via the osmot-
ic approach is inhaled mannitol, again studied in non-CF
bronchiectasis rather than specifically PCD.53 Although the
inhaled drug (400 mg BID) did not achieve its primary
outcome of reducing exacerbations, it did perform better
than placebo (low-dose mannitol) in slowing down the
time to first exacerbation and improving the quality of life
measures.
Deoxyribonuclease (Dornase-α)—Dornase-α is an enzyme
that hydrolyses eukaryotic DNA released from decaying
neutrophils to reduce mucus viscosity and aid airway clear-






Axonemal component Ultrastructure defect aPhenotype,
gene OMIM no.
PCD locus
MCIDAS 5q11.2 Required for cilia
biogenesis
Ciliary a/oligoplasia NA, 614086 NA
DNAH8b 6p21.1 ODA dynein HC NA 603337, NA NA
RPGRc Xp21.1 outer segment of Rod &
Con photoreceptors
Mixed 300455, 312610 NA
OFD1d Xq22 Centriole component,
required for cilia
biogenesis
NA 300209, 300170 NA
Abbreviations: CA, central apparatus; DA, dynein arm; DC, docking complex; HC, heavy chain; IC, intermediate chain; IDA, inner dynein arm; LC, light
chain; N-DRC, nexin-dynein regulatory complex; NA, not available; ODA, outer dynein arm; RS, radial spokes.
aOnline Mendelian Inheritance in Man (OMIM), http://www.omim.org/.
bCiliary ultrastructure not available50; however, DNAH8 is paralogous to DNAH5.
cCosegregation of X-linked PCD with X-linked retinitis pigmentosa.
dCosegregation of X-linked PCD with X-linked mental retardation.
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the non-CF bronchiectasis population, as studies show that
the drug is associated with pulmonary exacerbations and a
decline in lung function.55
Antibiotics
Given the propensity for chronic infection, as with other
forms of bronchiectasis, antibiotics are the cornerstone of
treatment for PCD exacerbations (usually associated with
an increase in cough, dyspnea, wheeze, with a change in
sputum volume or character, or purulence, or hemoptysis),
as they generally improve symptoms and hasten recov-
ery.56,57 Antibiotic therapy should be based on previous
respiratory culture data and previous therapeutic re-
sponses. Susceptibility patterns and clinical responses
may guide physicians between oral, inhaled, and intrave-
nous routes of administration. There are no randomized
data to support any particular drug, or route of administra-
tion, and clinical judgment is required; however, milder
exacerbations often respond to oral or oral–inhaled combi-
nations, while more significant exacerbations usually re-
quire systemic antibiotics (in combination, if gram-
negative organisms are cultured). There is a good deal of
interest in the development of inhaled antibiotics in recent
years in non-CF bronchiectasis, and over the next 5 to
10 years it is likely that there will be more approved drugs
with better evidence of efficacy available (a reduction in
exacerbation frequency, bacterial burden), for example,
inhaled aminoglycosides and quinolones.58–60 Early at-
tempts to eradicate newly acquired bacteria, especially P.
aeruginosa, are recommended; however, this has not
been shown to preserve lung function. Chronic or cycling
oral or inhaled antibiotics may be used in patients with
frequent exacerbation to try to improve quality of life,
reduce exacerbations, and (hopefully) stabilize lung
function.56,58,61,62
Anti-Inflammatories
A variety of anti-inflammatory agents including oral pred-
nisone, inhaled corticosteroids, and macrolides have been
used in airways disease associated with bronchiectasis.
Prednisone is generally not efficacious in the CF population
outside of coexistent asthma and ABPA, and there are no
studies in the PCD population. Inhaled corticosteroids have
not been shown to be beneficial in non-CF bronchiectasis.
The best data for “preventive” therapy come from recent
studies using oral macrolides, which have shown promising
outcomes in non-CF bronchiectasis, with reductions in ex-
acerbation frequency, delayed time to first exacerbation, and
reduced hospitalizations. It is unclear if this benefit is from an
anti-inflammatory or antimicrobial effect. Before initiating
therapy with a macrolide, patients should be tested for NTM,
in case macrolides should form part of a multidrug regimen,
and to avoid the emergence of resistance from chronic single-
agent macrolide use.63–65
Miscellaneous Approaches
Lung resection—Surgery may be considered in areas of
localized lung disease if it is causing severe systemic
symptoms, frequent exacerbations, or recurrent/life-
threatening hemoptysis despite aggressive medical
therapy. Patients in such situations have undergone
successful resection, but long-term data are lacking.66
Often the diffuse nature of disease elsewhere in the lung
mitigates against the likelihood of success in resecting
more diseased parts of the lung.
Lung transplant—PCD patients undergoing double-lung
transplant generally have good survival outcomes. The usual
concerns pertain to candidacy for the procedure, and also
specifically include multiple drug-resistant organisms, and
poor nutritional status. Interestingly, patients with situs
inversus do not pose any additional risk to posttransplant
outcomes; the anatomic disorientation is challenging but not
a contraindication.67
Extra-pulmonary Disease Management
Otitis media—Management may be controversial, especially
in the pediatric community. The long-term sequelae of chron-
ic disease in the upper airway include conductive hearing loss,
delayed speech and language development, and cholesteatoma
formation. Standard medical therapy is recommended for
acute episodes. There are no enough data on surgical tympa-
nostomy to make a definitive statement regarding its utility;
experts argue against the utility of this approach.27Regular
audiology assessments are encouraged.68,69
Chronic sinusitis—As with CF, the sinuses are usually
involved. Management includes nasal steroids, nasal lavage
and intermittent antibiotic lavages, and systemic antibiotics.
Otolaryngology evaluation for surgery and polypectomy to
promote sinus drainage is helpful for patients’ refractory to
medical therapy.70
Infertility—Male infertility is secondary to sperm immo-
tility and assisted fertilization techniques such as intra-
cytoplasmic sperm injections are promising. Female
infertility is secondary to sluggish fallopian tube transit
time, and direct ovum harvesting with in vitro fertilization
leads to successful pregnancy.
Prognosis
As compared with CF, the disease severity and deterioration
in lung function is less marked, especially with appropriate
medical therapy. A study by Ellerman and Bisgaard reported
that adults hadworse lung function at the time of diagnosis as
compared with adolescents; however, once diagnosed and
therapy started, no further lung deterioration was noted.71
However, other studies have shown progression to severe
lung disease before adulthood. These discrepancies in severi-
ty and survival may relate at least in part to the genetic and
phenotypic heterogeneity of PCD, as well as the usual aspects
of access to care, socioeconomic backgrounds of patients, and
accompanying comorbidities. Overall, the majority of pa-
tients with PCD appear to have a near-normal life expectancy
when compliant with recommended therapies. A minority of
patients develop progressive severe bronchiectasis, end-stage
lung disease, and early death, unless they undergo lung
transplant.71
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Summary and into the Future
In the past two decades, much has been learned about PCD.
Accurate and earlier diagnosis is possible, and access to
specialized centers has become easier. Standardized care
at specialized centers using a multidisciplinary approach is
expected to improve outcomes. The recent creation of the
PCD foundation has facilitated the creation of a network of
PCD clinical centers to help achieve this goal. As the network
grows, and clinicians and research scientists accumulate
more data from growing numbers of PCD patients, clinical
care and knowledge will undoubtedly improve. In parallel,
genetic correlates with larger clinical datasets have shown
that PCD is a genetically heterogenous diseasewith different
mutations in several genes resulting in a phenotype spec-
trum, across many races and ethnic groups. The severity of
disease ranges from mild to severe. Delays in recognition
may result in the development and progression of irrevers-
ible lung disease. In CF, early identification and diagnosis
leads to early treatment and frequent monitoring to de-
crease morbidity and mortality, and one assumes the same
principles apply to PCD, despite differences in pathogenesis.
Still, it must be remembered that PCD is not the same as CF,
and management is not identical. Without large numbers of
patientswith PCD, there has hitherto been little incentive for
industry to pursue drug development; thus, currently we
rely on studies in non-CF bronchiectasis (mucoactive agents,
macrolides, inhaled antibiotics). However, as noted earlier,
with the creation of clinical and research networks, with
improved identification, and more accurate diagnosis of
PCD, we can expect larger cohorts of PCD patients available
to participate in longitudinal studies of the natural history of
the disease, as well as studies of novel therapies, with the
goal of improving clinical care and outcomes in this rare
disease.
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